Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Sells 1,259 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc sold 1,259 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $31.06, for a total value of $39,104.54. Following the completion of the sale, the insider directly owned 141,029 shares of the company’s stock, valued at $4,380,360.74. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc acquired 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc acquired 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.16 per share, with a total value of $169,100.80.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:SNSE traded up $0.61 during midday trading on Friday, reaching $20.43. 40,583 shares of the company’s stock were exchanged, compared to its average volume of 223,112. The firm’s 50 day simple moving average is $29.11 and its two-hundred day simple moving average is $17.85. The stock has a market cap of $27.40 million, a price-to-earnings ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Equities research analysts predict that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SNSE. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Leerink Partners assumed coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $40.00.

Trending Headlines about Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.